Diverse Ancestry Study in IBD
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06042387 |
Recruitment Status :
Recruiting
First Posted : September 18, 2023
Last Update Posted : September 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective:
To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD in diverse ancestries:
African, African American, Black, Afro-Caribbean, Afro-Latino/a/x, Latino/a/x, Hispanic, or any other Black or Latin or indigenous ancestry.
Condition or disease | Intervention/treatment |
---|---|
Ulcerative Colitis Healthy Crohn Disease Inflammatory Bowel Diseases | Genetic: Blood or saliva sample collection |
Background:
Inflammatory bowel disease (IBD) is a chronic, and often disabling, disorder of the intestines characterized by dysregulation of mucosal immune response. Recent data suggests that the incidence and prevalence rates among diverse populations may be increasing due to constantly changing environmental exposures. The goal of the study is to identify susceptible genes that contribute to the pathogenesis of IBD in individuals who self-identify as African, African American, Black, Afro-Caribbean, Afro-Latino/a/x, Latino/a/x, Hispanic, or any other Black or Latin or indigenous ancestry.
Study Type : | Observational |
Estimated Enrollment : | 150 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Diverse Ancestry Study in Inflammatory Bowel Disease |
Actual Study Start Date : | May 1, 2022 |
Estimated Primary Completion Date : | May 2027 |
Estimated Study Completion Date : | September 2027 |

Group/Cohort | Intervention/treatment |
---|---|
IBD Subjects
Self-identify as: Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) Any age |
Genetic: Blood or saliva sample collection
Blood or saliva sample & clinical data collection |
Controls
Self-identify as: Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry No personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss Any age |
Genetic: Blood or saliva sample collection
Blood or saliva sample & clinical data collection |
- Genetics studies in diverse ancestries [ Time Frame: 2022-2027 ]Whole Exome Sequencing (+/- other sequencing) is planned to assess genetic diversity in diverse populations.
Biospecimen Retention: Samples With DNA
Participation involves:
One-time blood (preferred) or saliva sample Collection of clinical data

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Subject must self-identify as African, African American, Black, Afro-Caribbean, Afro-Latino/a/x, Latino/a/x, Hispanic, or any other Black or Latin or indigenous ancestry
- Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
- Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
- Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
- Any age
Exclusion Criteria:
- Doesn't self-identify as African, African American, Black, Afro-Caribbean, Afro-Latino/a/x, Latino/a/x, Hispanic, or any other Black or Latin or indigenous ancestry
- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06042387
Contact: Joanne Stempak, MSc | 4165864800 ext 8399 | joanne.stempak@sinaihealth.ca | |
Contact: Jenny Lee, MKin | 416-586-4800 ext 2318 | jenny.lee2@sinaihealth.ca |
Canada, Ontario | |
Sinai Health System | Recruiting |
Toronto, Ontario, Canada, M5G 1X5 | |
Contact: Joanne Stempak, MSc 4165864800 ext 8399 joanne.stempak@sinaihealth.ca | |
Contact: Jenny Lee, MKin 4165864800 ext 2318 IBD.research@sinaihealth.ca |
Principal Investigator: | Mark Silverberg, MD PhD | Sinai Health System |
Responsible Party: | Mark Silverberg, Dr., Mount Sinai Hospital, Canada |
ClinicalTrials.gov Identifier: | NCT06042387 |
Other Study ID Numbers: |
02-0234-E U01DK062423 ( U.S. NIH Grant/Contract ) |
First Posted: | September 18, 2023 Key Record Dates |
Last Update Posted: | September 18, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Crohn Disease Intestinal Diseases Inflammatory Bowel Diseases |
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |